Articles tagged with Vaccine Development
Researchers at The Wistar Institute have developed a novel antigen-cloning technique that may boost efforts to develop a melanoma vaccine. The new approach has been used to identify a tumor antigen called ribosomal protein L8 (RPL8), which has the potential to elicit both helper T cell and cytotoxic T-lymphocyte responses.
Professor Ian Frazer, a renowned cancer vaccine innovator, has been awarded the prestigious Florey Medal for his groundbreaking work on cervical cancer prevention. The award recognizes the significant public health impact of his research, which aims to control cervical cancer rates in developing countries.
Researchers developed an experimental vaccine that reduces stillbirths among rodents born to mothers infected with cytomegalovirus, a common virus causing mental retardation and hearing loss. The vaccine was found to greatly reduce the total amount of virus in mothers' blood and mortality rates among offspring.
Researchers at Harvard University have created a novel spraying method for delivering the most common tuberculosis (TB) vaccine, offering needle-free delivery and greater stability. This breakthrough could improve TB care and slow the spread of HIV/AIDS in developing countries.
Developing an H5 vaccine faces hurdles in current egg production methods and the molecule's ability to stimulate an immune reaction, requiring two shots for full immunization. The ideal adjuvant must still be found to boost vaccine effectiveness.
Developing countries face a critical shortage of pandemic influenza vaccines, with only 500 million doses available globally. The WHO is urging international agreement to ensure affordable vaccine access for these nations, demonstrating global solidarity in the face of the next pandemic threat.
A novel spray drying method has been developed to preserve and deliver the most common tuberculosis (TB) vaccine, promising greater stability at room temperature and use in needle-free delivery. This technique could provide a better approach for vaccination against TB and help prevent the spread of HIV/AIDS in developing countries.
Researchers have identified certain proteins that can protect against Chlamydia infection and are working towards developing a vaccine for adolescent women. The funding boost will allow QUT to evaluate the effectiveness of prevention methods, including a potential patch-based delivery system.
A study published in Nature reveals the structural basis of botulinum toxins' interaction with nerve cells, allowing for improved understanding and potential new treatments for botulism, food poisoning, and nervous system diseases. The discovery could lead to the development of new drugs, vaccines, and antibody therapies.
A team of Yale biomedical engineers and cell biologists received a $1-million grant to create smart nanoparticles for vaccine delivery. They aim to develop materials that mimic biological vectors, evading normal barriers and stimulating antigen-presenting cells.
Research identifies receptor on host cells that triggers immune response to tuberculosis, which could enable novel vaccine development to boost immunity. The discovery also highlights the importance of targeting TB in HIV-infected patients, who are highly susceptible to the disease.
Scientists have developed a vaccine that protects mice against the 1918 influenza virus, which killed 50 million people worldwide. The vaccine works by stimulating antibodies capable of neutralizing the virus, providing a potential solution to future pandemic flu strains.
The Journal of Infectious Diseases has published a supplement offering current information on pandemic and seasonal influenza, featuring leading experts discussing research and recommendations. The article highlights key findings on disease surveillance, vaccine manufacturing, and public health response plans.
Regenerative medicine holds promise for affordable treatments and offsetting donor shortages, particularly for diabetes, heart disease, and infectious diseases. The study prioritizes 10 applications, including novel insulin replacement methods, regenerating failed heart muscle, and engineered immune cells.
Despite an increase in drug development for killer diseases, researchers argue that more incentives and access guarantees are needed to address the lack of economic demand. The rise of public-private partnerships (PPPs) is also cited as a contributing factor.
The study found a significant decrease in the age-adjusted HSV-2 seroprevalence from 17.0% in 1999-2004 to 21.0% in 1988-1994, with decreases especially concentrated among persons aged 14 to 19 years. The prevalence of genital herpes caused by HSV-1 may be increasing.
The International AIDS Vaccine Initiative proposes new scientific and policy initiatives to accelerate AIDS vaccine development, fostering capacity building in developing countries. The Blueprint highlights the need for a dynamic global research and development program with clear spending targets and equitable financial burden-sharing.
A Kenyan study confirms that routine Hib vaccination significantly reduced invasive Hib disease to 88% below baseline. This finding suggests that virtual elimination of the devastating disease is possible if more countries adopt the vaccine as part of their national immunization programs.
A new study outlines an innovative approach to create a CMV vaccine using recombinant technologies. Researchers have successfully introduced human CMV genes into mouse CMV, resulting in a novel form of the virus that can trigger an immune response without sustaining infection.
J-P Garnier, GSK CEO, emphasizes the company's commitment to providing affordable HIV drugs and vaccines for diseases affecting the developing world. He highlights GSK's efforts to introduce modern HIV drugs at lower prices and protect innovation through patents.
Sharon Witonsky, a clinician and researcher at Virginia Tech, has received the Pfizer Award for her work on EPM, a neurologic disease that affects horses. Her research aims to discover the mechanism of Sarcocystis neurona's effects on horses and develop more effective diagnostic tests and vaccines.
The introduction of Gardasil in the USA is proving problematic due to social and cultural resistance. The Bill and Melinda Gates Foundation has donated $27.7 million to PATH to research introducing the vaccine in developing countries, where Merck and GSK can assist by identifying cultural barriers.
A new H5N1 vaccine has demonstrated cross-protection in ferrets against different variants of the virus, offering a promising solution for stockpiling in the event of a human outbreak. The vaccine was shown to completely protect ferrets from infection and reduce viral multiplication.
Dental caries is a widespread and increasing problem globally, with 5 billion people affected. Forsyth researchers aim to develop a vaccine targeting bacterial accumulation on teeth, with initial focus on mucosal vaccines for young children.
Routine childhood pneumococcal vaccination has the potential to save millions of lives, particularly children under five years old. The seven-valent vaccine is already licensed and in use in over 60 countries, and formulations with additional serotypes are being developed to target strains commonly causing death and disability.
A new potential vaccine against deadly leishmaniasis has been developed by a research group led by Peter H. Seeberger, combining a virosome delivery system with a synthetic carbohydrate antigen. This innovative approach aims to overcome the limitations of existing vaccines and provide a strong protective action against the disease.
Researchers identify matrix protein as critical component in VSV's ability to invade cells and replicate, leading to potential vaccine development and anti-viral agents. The discovery also provides insights into how viruses shut down cell protein-making capabilities.
Researchers at Rice University propose a novel approach to combat Dengue virus by administering multiple vaccines simultaneously at different locations on the body, bypassing immunodominance and enhancing immunity against all four closely related viruses. This strategy has implications for other diseases such as HIV and cancer.
Researchers analyzed data from nearly 63,000 patients hospitalized for pneumonia between 1999 and 2003. Vaccination was associated with a 40-70% lower risk of death during hospitalization compared to unvaccinated or unknown status patients.
Researchers sequenced and analyzed over 1.8 million genetic codes to determine functions of genes involved in polysaccharide capsule production. The new vaccine protects children from many common serotypes, but monitoring is needed to track potential changes in capsular types.
The University of Pittsburgh has established an Immune Modeling Center to study immune responses to infectious diseases using mathematical modeling. The center will focus on understanding innate and adaptive immune responses to influenza A virus, Mycobacterium tuberculosis, and Francisella tularensis.
The Biodesign Institute is developing a subunit vaccine against tularemia using unique technologies, including high-throughput gene building and gene expression measurement. This approach aims to produce an effective and safe vaccine by identifying the best pathogen components to elicit an immune response.
Researchers found that identical twins infected with the same HIV strain had different T-cell receptor characteristics, indicating a random and unpredictable immune response. This discovery challenges the idea of developing a single, universal vaccine for everyone.
The RTS,S/AS02A vaccine reduced clinical malaria episodes by 35% and severe malaria episodes by 49%. The study followed 14,442 children who received a three-dose regimen of the vaccine in 2003 for an 18-month follow-up period.
Pall Corporation's total process management approach can improve vaccine production economics by reducing time, safety risks, and expenses. The use of scalable and disposable technologies enables efficient processing of larger volumes, addressing the need for increased manufacturing capacity in response to pandemic threats.
Researchers outline new approaches to help developing countries address neglected diseases by pooling resources through health innovation networks. The recommended approach emphasizes harmonized development in six sectors, including manufacturing, research and development, and intellectual property systems.
Researchers reconstructed the 1918 flu virus using reverse genetics, a technique developed by Mount Sinai School of Medicine researchers. The study reveals that the virus is extremely virulent in mice and grows rapidly in human lung cells.
The National Institute of Allergy and Infectious Diseases has awarded $60 million to support the development of new tularemia vaccines. This contract is part of a larger NIAID biodefense awards package, which includes funding for Regional Biocontainment Laboratories and research on high-priority pathogens such as anthrax and smallpox.
Robert Gallo emphasizes the need for a rational approach to HIV vaccine development, ignoring empirically driven methods and focusing on solid knowledge of HIV biology. He suggests leveraging the Gates's Foundation's Grand Challenge for Global Health to find practical solutions to scientific roadblocks.
A report on vaccine markets is criticized for favoring large firms and delaying access to effective vaccines. The author recommends using advanced purchase commitments as a complement to research funding.
Researchers find B-1a cells regulate innate immunity, while B-1b cells drive adaptive long-term response to infections. The discovery sheds light on vaccine action and potential insights into designing vaccines.
A U of T study identified barriers to future HIV vaccine acceptance, including concerns about power dynamics, affordability, and stigma. Researchers found that women viewed vaccination as empowering and a way to protect themselves and their children.
CHAVI will focus on solving key questions about HIV interactions with the body and designing improved vaccines. The center will also evaluate promising candidates in small-scale clinical trials.
The NIAID-funded CHAVI center will focus on understanding early stages of HIV infection, developing new research tools, and designing improved HIV vaccines. The center aims to accelerate the development of a safe and effective preventive vaccine for HIV/AIDS through collaborative research.
Scientists have sequenced the genomes of three parasites responsible for sleeping sickness, Chagas disease, and leishmaniasis, providing critical information for drug and vaccine development. The research identified core genes that could serve as targets for effective drugs against all three parasites.
Researchers are developing genetically altered malaria parasites to stimulate immunity against the disease. The goal is to boost the immune system in a similar way to how the altered polio bacteria triggers immunity against polio.
A new study estimates that dengue fever costs over $13 million annually, equivalent to 940,000 lost workdays of output. A potential vaccine could offset 87% of treatment costs, reducing the economic burden on governments and households.
The Yale project aims to create a predictive model system for vaccine testing, addressing the need to predict vaccine safety and effectiveness. The team will study a novel solution using mice engineered with human immune systems, generated with technology developed in Switzerland.
A study found that routine immunisation of infants with the Haemophilus influenzae type b (Hib) vaccine significantly reduced meningitis incidence rates in The Gambia. The researchers hope their findings will encourage other developing countries to adopt Hib vaccination programmes, helping achieve the United Nations' goal of decreasing...
The project aims to formulate a vaccine with a safe, low-cost additive derived from weakened Salmonella bacteria, which can enhance the immune response. A single-dose oral vaccine is also being developed, making it more accessible and practical for use in developing countries.
Researchers have developed a new vaccine that is 100 percent effective in protecting monkeys from infection with deadly viruses Ebola and Marburg. The vaccine targets dendritic cells, which are the same cells attacked by these viruses.
Dr. Albert Z. Kapikian receives the Sabin Gold Medal for developing the first licensed rotavirus vaccine, saving millions of lives worldwide. His pioneering work in electron microscopy and virus characterization has been widely recognized by NIAID Director Anthony Fauci and H.R. Shepherd.
NIAID has awarded $27 million to institutions and companies to develop medical countermeasures against Category A bioterror agents, including botulinum toxin and Ebola. The awards will support the development of new treatments and therapies using promising scientific discoveries.
The US vaccine system is fragile and needs significant improvements, the authors report. Despite record low levels of vaccine-preventable diseases and high immunization rates among children, supply chain issues, cost concerns, and safety threats threaten to derail progress.
Aeras and UCLA announce a license deal for rBCG30, a live recombinant vaccine technology developed at UCLA's David Geffen School of Medicine. The vaccine has shown promising results in initial clinical studies and holds potential to reduce TB disease burden globally.
Researchers at Yale University have identified a molecule that detects parasitic infections in humans, shedding light on how the body recognizes parasites. The discovery of Toxoplasma profilin and TLR11 provides crucial information for developing novel strategies to combat parasitic infections.
A four-year study published in the New England Journal of Medicine confirms RSV as a substantial burden of disease in adults, similar to influenza A. The study calls for the development of an RSV vaccine for elderly and high-risk adults.
Using informatics and computer modelling, researchers can speed up vaccine development by identifying common patterns in 'foreign' protein sequences. This approach has the potential to significantly reduce the number of proteins that need to be experimentally tested.
A new influenza vaccine developed using insect cells can produce a strong immune response in humans and may be scaled up for commercial manufacture. This rapid method uses a purified concentration of hemagglutinin to elicit an immune response against specific flu strains.
The National Institute of Allergy and Infectious Diseases (NIAID) is soliciting applications for Clinical Trials Units to lead in the development and evaluation of treatments, prevention strategies, and vaccines for HIV/AIDS. The selected units will focus on interventions that can be employed in resource-limited settings.